This project uses the sacsin mutant mouse and mice lacking SARM1 to ask whether the progression of the cell loss in ARSACS can be slowed or prevented by removing SARM1. A positive outcome would make ARSACS a strong candidate for this therapeutic strategy.
Duration : 18 months
Dr. Thomas L. Schwarz, Professor, F.M. Kirby Neurobiology Center Children’s Hospital, Boston and Dept.of Neurobiology
Harvard Medical School CLSB 12-130, 3 Blackfan Street, Boston, MA 02115
Tel:(617)-919-2219 (office) or (617)-919-2264 (lab)